Only leftover biological samples were used to measure blood calcitonin
and, when possible, ionized calcium.
However, immunohistochemical staining of the sample for calcitonin
yielded positive results.
No prior study has compared therapeutic doses of alendronate and calcitonin
in a parallel design," said Dr.
We are very pleased with the results of this study, which demonstrate that our transdermal Calcitonin
is safe and as efficacious as a subcutaneous injection," said Dr.
About Tarsa Therapeutics Tarsa is developing Ostora, a novel oral formulation of calcitonin
for the treatment of postmenopausal osteoporosis in women greater than five years post menopause when alternative treatments are not suitable.
Novartis and Nordic Bioscience also have confirmed that a concurrent three-year Phase III study 2303 of oral calcitonin
for the treatment of osteoporosis is proceeding as planned.
In a Phase III global, randomized, double-blind trial in postmenopausal women with osteoporosis, known as the ORACAL trial, Tarsa's once-daily oral calcitonin
demonstrated superiority to both placebo and nasal calcitonin
spray in increasing bone mineral density at the lumbar spine after 48 weeks.
1] Tarsa is developing an oral calcitonin
tablet for the treatment and prevention of post-menopausal osteoporosis.
In October 2009, we licensed our Phase III oral calcitonin
program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Unigene is the manufacturer of Fortical Nasal Spray, a calcitonin
containing product indicated for the treatment of osteoporosis that is distributed in the USA by Upsher Smith Laboratories, Inc.
The meta-analysis, conducted by researchers at the Center for Sensory-Motor Interaction in the Department of Health Science and Technology at Aalborg University in Denmark, examined independent pre-clinical and clinical studies spanning nearly 45 years of the possible intrinsic analgesic properties of calcitonin
, with special focus on the challenges in the musculoskeletal system.
today announced that a Phase II trial of its oral recombinant salmon calcitonin
in the prevention of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, clinically relevant improvements in bone mineral density (BMD) at the lumbar spine.
Tarsa) on October 20, 2009 in association with its oral calcitonin
Phase III expenditures.
Tarsa to Provide Expert Assistance to Italian Marketer of Nasal Calcitonin
Spray, Whose Request for Reexamination of Recent CHMP Recommendation Has Been Accepted
is approved for the treatment of osteoporosis, but its use has been limited as it is currently available only in intranasal and injectable forms.